Athersys (ATHX) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ATHX vs. SPRB, AFMD, OGEN, PTN, GRAY, GRTX, VCNX, ONCT, ADXS, and BPTHShould you be buying Athersys stock or one of its competitors? The main competitors of Athersys include Spruce Biosciences (SPRB), Affimed (AFMD), Oragenics (OGEN), Palatin Technologies (PTN), Graybug Vision (GRAY), Galera Therapeutics (GRTX), Vaccinex (VCNX), Oncternal Therapeutics (ONCT), Ayala Pharmaceuticals (ADXS), and Bio-Path (BPTH). Athersys vs. Its Competitors Spruce Biosciences Affimed Oragenics Palatin Technologies Graybug Vision Galera Therapeutics Vaccinex Oncternal Therapeutics Ayala Pharmaceuticals Bio-Path Spruce Biosciences (NASDAQ:SPRB) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings. Does the media favor SPRB or ATHX? In the previous week, Spruce Biosciences and Spruce Biosciences both had 1 articles in the media. Athersys' average media sentiment score of 0.75 beat Spruce Biosciences' score of 0.00 indicating that Athersys is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Athersys 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SPRB or ATHX more profitable? Athersys has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Athersys' return on equity of 0.00% beat Spruce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Spruce Biosciences-555.23% -62.10% -47.49% Athersys N/A N/A -223.03% Which has more volatility and risk, SPRB or ATHX? Spruce Biosciences has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, indicating that its stock price is 190% less volatile than the S&P 500. Do institutionals and insiders hold more shares of SPRB or ATHX? 91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 19.4% of Athersys shares are owned by institutional investors. 6.9% of Spruce Biosciences shares are owned by insiders. Comparatively, 0.0% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings and valuation, SPRB or ATHX? Spruce Biosciences has higher revenue and earnings than Athersys. Spruce Biosciences is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpruce Biosciences$4.91M0.63-$47.92M-$1.32-0.06Athersys$146K0.00-$72.53M-$2.03N/A Do analysts prefer SPRB or ATHX? Spruce Biosciences presently has a consensus target price of $1.75, suggesting a potential upside of 2,307.15%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Spruce Biosciences is more favorable than Athersys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummarySpruce Biosciences beats Athersys on 9 of the 13 factors compared between the two stocks. Get Athersys News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHX vs. The Competition Export to ExcelMetricAthersysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$833K$789.32M$5.51B$8.95BDividend YieldN/A4.84%5.25%4.04%P/E Ratio0.001.3028.0220.16Price / SalesN/A227.08405.99173.08Price / CashN/A23.4437.0657.97Price / BookN/A6.138.125.62Net Income-$72.53M-$27.58M$3.16B$248.50M Athersys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHXAthersysN/AN/AN/AN/A$833K$146K0.0024News CoverageSPRBSpruce Biosciences2.1887 of 5 stars$0.07+0.7%$1.75+2,313.8%-87.1%$3.06M$4.91M-0.0820Gap DownAFMDAffimed2.9277 of 5 stars$0.18-34.9%$3.62+1,895.9%-96.4%$2.92M$877K0.00200Gap DownHigh Trading VolumeOGENOragenics0.0706 of 5 stars$3.82-5.7%N/A-95.5%$2.73M$40K-0.545Gap DownPTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeGRAYGraybug VisionN/A$1.43flatN/A-64.2%$2.25MN/A-0.8327Gap UpHigh Trading VolumeGRTXGalera Therapeutics0.2818 of 5 stars$0.03-4.6%N/A-79.7%$2.15MN/A-0.0830Gap DownVCNXVaccinex0.4161 of 5 stars$0.73flatN/A-87.0%$1.90M$388K-0.0240Gap UpONCTOncternal TherapeuticsN/A$0.53flat$10.00+1,799.0%N/A$1.56M$790K-0.0530ADXSAyala PharmaceuticalsN/A$0.03+22.9%N/A-19.8%$1.42M$3.24M0.0020BPTHBio-Path0.7328 of 5 stars$0.17-3.4%$20.00+11,664.7%-89.9%$1.41MN/A0.0010 Related Companies and Tools Related Companies Spruce Biosciences Competitors Affimed Competitors Oragenics Competitors Palatin Technologies Competitors Graybug Vision Competitors Galera Therapeutics Competitors Vaccinex Competitors Oncternal Therapeutics Competitors Ayala Pharmaceuticals Competitors Bio-Path Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHX) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athersys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
